Abstract:OBJECTIVE:To investigate the effects of Adp53 and F56 on the growth and lung metastasis of breast cancer.METHODS:The BICR-H1 cells were inoculated into the mammary fatty pad of BALB/C nude mice and NOD/SCID mice to establish breast cancer model. Then the nude mice with xenograft tumor were randomized into group Adp53+F56, Adp53, F56 and control. The NOD/SCID mice with xenograft tumor were randomized into group Adp53+F56, Adp53, F56, Adlacz and control. They were treated for 3 weeks according to the plan, diversity of the volume and histopathology of xenograft tumor of nude mice was observed and the expressions of p53 and VEGF gene, and microvessel density (MVD) were detected by immunohistochemistry. Lung metastasis of breast cancer in NOD/SCID mice was observed.RESULTS:(1) Intratumoral injections of Adp53, F56, and their combination resulted in an inhibition on the growth of xenograft tumor of BICR-H1 cells. The ultimate relative growth volumes of groups Adp53+F56, Adp53, F56 and control were 2.47,4.37,4.69 and 12.49 respectively. (2) After treatment, P53 positive rate of group Adp53+F56, Adp53 increased 9.4%, 6.3% than before respectively, but compared with control group, the difference is not significant (P=0.693); VEGF protein of group Adp53+F56, Adp53 and F56 decreased 21.9%, 9.4% and 3.1% than before respectively, but compared with control group, the difference was not significant (P=0.284). Necrosis and decrease of vessel in the tumor and morphological change of endothelium were observed under light microscope in the groups Adp53+F56, Adp53 and F56. MVD estimated by FVIII-RA staining of group Adp53+F56, Adp53 and F56 were 14.50+/-2.54, 16.28+/-3.44 and 18.06+/-7.66, compared with control group(24.93+/-6.53), the difference is significant (P=0.000). (3) The average number of lung metastasis of NOD/SCID mice in group Adp53+F56, Adp53 and F56 were 1.143+/-0.378, 2.750+/-0.886 and 3.375+/-0.518 respectively, lower than Adlacz group(5.000+/-0.816) and control group (5.670+/-0.817) obviously (P=0.000).CONCLUSION:Adp53 combined with F56 can greatly inhibit growth and metastasis of breast cancer in vivo. The mechanism of anti-tumor effects of Adp53 and F56 may be related to the anti-angiogenesis effect on malignant tumor through inhibiting the expression and activity of VEGF.

A Vegfr1 Antagonistic Peptide Inhibits Tumor Growth and Metastasis Through Vegfr1-Pi3k-Akt Signaling Pathway Inhibition

Suppression of Tumor Growth and Metastasis by a VEGFR-1 Antagonizing Peptide Identified from a Phage Display Library.

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]

Dual Blockade of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF-2) Exhibits Potent Anti-Angiogenic Effects.

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

A Novel Fgfr1-Binding Peptide Exhibits Anti-Tumor Effect On Lung Cancer By Inhibiting Proliferation And Angiogenesis

FP3: a Novel VEGF Blocker with Anti-Angiogenic and Anti-Tumor Effects.

A Novel Synthetic Small Molecule YF-452 Inhibits Tumor Growth Through Antiangiogenesis by Suppressing VEGF Receptor 2 Signaling

A Novel Peptide Specifically Binding to VEGF Receptor Suppresses Angiogenesis in Vitro and in Vivo

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Antitumor Effect of FP3 in a Breast Cancer Xenograft Model.

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis

Systemic Inhibition of Tumor Growth by Soluble Flk-1 Gene Therapy Combined with Cisplatin

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

[Inhibitory Effect of Adp53 and F56 on Growth and Metastasis of Transplantation of the Breast Tumor in Mice].

VEGFR2-targeted antibody fused with IFN mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity

[Cloning, Expression of Soluble VEGFR2 Fragment and Its Effect on Tumor Angiogenesis].